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Abstract 
BACKGROUND: The HOX genes are a family of transcription factors that help to 
determine cell and tissue identity during early development, and which are also over-
expressed in a number of malignancies where they have been shown to promote cell 
proliferation and survival. 
METHODS: HOX function was inhibited using the HXR9 peptide. HOX gene 
expression was assessed by RNA extraction from cells or tissues followed by 
quantitative PCR, and siRNA was used to block the expression of the HOX target 
gene, cFos. In vivo modelling involved a mouse flank tumour induced by inoculation 
with LNCaP cells. 
RESULTS: In this study we show that the expression of HOX genes in prostate 
tumours is greatly increased with respect to normal prostate tissue. Targeting the 
interaction between HOX proteins and their PBX cofactor induces apoptosis in the 
prostate cancer derived cell lines PC3, DU145 and LNCaP, through a mechanism 
that involves a rapid increase in the expression of cFos, an oncogenic transcription 
factor. Furthermore, disrupting HOX / PBX binding using the HXR9 antagonist blocks 
the growth of LNCaP tumours in a xenograft model over an extended period. 
CONCLUSION: The HOX genes are a potential therapeutic target in prostate cancer. 
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Background 
Prostate cancer is the most prevalent male malignancy with just under one million 
new cases worldwide each year [1]. Treatment pathways for this disease are 
relatively well defined and include surgery, radiotherapy  and / or hormonal therapy. 
While the majority of patients with early stage disease are cured, 10-15% patient still 
develop locally recurrent or metastatic disease and have a significantly reduced 
survival rate [2]. Despite the general adoption of docetaxel chemotherapy agents and 
novel agents such as abiraterone [3], there is still an urgent need to develop effective 
new treatments, and therefore  necessary to explore new target proteins and 
intracellular signalling pathways.  
 
Recently, considerable interest has been shown in genes that play key roles in 
defining the identity of cells and tissues in early development and which therefore 
also have important regulatory roles in cell proliferation and survival. One group of 
genes that fit into this category are the HOX family of transcription factors [4]. HOX 
proteins are characterised in part by a highly conserved homeodomain that mediates 
DNA binding, together with a defined set of co-factors that modify their function 
including members of PBX family [5-7]. The pro-proliferative and anti-apoptotic roles 
of some HOX genes in development make them potential oncogenes, and indeed 
there are numerous reports of HOX overexpression in a range of malignancies, 
including prostate cancer [4, 8-11]. Although definitive oncogenic roles for some HOX 
genes have been described, in general studies on the function of individual HOX 
genes in cancer have been complicated by the high levels of sequence identity and 
functional redundancy exhibited by most members [12, 13]. This functional 
redundancy in particular has made the results of conventional knock-down studies 
(using for example siRNA) hard to interpret. As an alternative approach we 
developed a peptide, HXR9 that acts as a competitive antagonist of the interaction 
between HOX proteins and their PBX co-factor. This interaction is mediated by a 
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conserved hexapeptide sequence shared by the majority of HOX proteins, and HXR9 
can globally repress HOX function through mimicking this peptide [14-19]. In this 
study we show that prostate tumours have a highly dysregulated pattern of HOX 
expression and that HXR9 induces apoptosis in prostate cancer derived cell lines 
through a mechanism that involves a rapid increase in expression of the cFos gene. 
Furthermore, HXR9 can block prostate tumour growth in vivo for an extended period, 
suggesting that HXR9 or its derivatives might represent a possible therapeutic option 
for locally recurrent prostate cancer. 
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Methods 
 
Cell lines and culture 
The cell lines used in this study were DU145 (derived from a prostate carcinoma 
brain metastasis)[20], PC3 (derived from a prostate adenocarcinoma bone 
metastasis)[21], LNCaP (derived from a prostate carcinoma lymph node 
metastasis)[22], and WPMY-1 (derived from normal prostate stroma and 
immortalised with SV40 Large T antigen)[23]. They were obtained from the ATCC 
through LGC Standards Ltd (UK), and were cultured according to the instructions on 
the LGC Standards website. 
 
Synthesis of HXR9 and CXR9 peptides 
HXR9 is an 18 amino acid peptide consisting of the previously identified hexapeptide 
sequence that can bind to PBX and nine C-terminal arginine residues (R9) that 
facilitate cell entry. The N-terminal and C-terminal amino bonds are in the D-isomer 
conformation, which has previously been shown to extend the half-life of the peptide 
to 12 hours in human serum[15]. CXR9 is a control peptide that includes the R9 
sequence but lacks a functional hexapeptide sequence due to a single alanine 
substitution. All peptides were synthesized using conventional column based 
chemistry and purified to at least 80% (Biosynthesis Inc, USA). The sequences of the 
peptides are as follows: 
HXR9: WYPWMKKHHRRRRRRRRR (2700.06Da) 
CXR9: WYPAMKKHHRRRRRRRRR (2604.14Da) 
 
Primary prostate tumour RNA 
Total RNA from prostate tumours and normal prostate tissue was obtained from 
OriGene Technologies Ltd, Rockville, USA. Six normal prostate tissue samples 
(median age of donor 56 years, range 52–71 years), and 17 prostate tumour samples 
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(median age of donor 60 years, range 48–73 years) were included in the analysis. Of 
the prostate tumour samples, 5 were Gleason grade 6, 8 were Gleason grade 7, 1 
was Gleason grade 8, and 3 were Gleason grade 9. Reverse transcription and QPCR 
were performed as described below. 
 
 RNA purification and reverse transcription 
Total RNA was isolated from cells using the RNeasy Plus Mini Kit (Qiagen) by 
following the manufacturer’s protocol.  The RNA was denatured by heating to 65ºC 
for 5 minutes.  cDNA was synthesized from RNA using the Cloned AMV First Strand 
Synthesis Kit (Invitrogen) according to the manufacturer’s instructions. 
 
Quantitative PCR 
Quantitative PCR was done using the Stratagene MX3005P real-time PCR machine 
and the Brilliant SYBR Green QPCR Master Mix (Stratagene).  Oligonucleotide 
primers were designed to facilitate the unique amplification of -actin, c-Fos, and 
each HOX gene. 
 
Mice and in vivo trial 
All animal experiments were conducted in accordance with the United Kingdom Co-
ordinating Committee on Cancer Research (UKCCCR) guidelines for the Welfare of 
Animals in Experimental Neoplasia[24]. The mice were kept in positive pressure 
isolators in 12 hour light / dark cycles and food and water were available ad libitum. 
Athymic nude mice were inoculated subcutaneously with a suspension of 2.5 
× 106 LNCaP cells in culture media (100 µl).  Once tumours reached volumes of 
approximately 100 mm3, mice received an initial dose of 100 mg/Kg CXR9 or HXR9 
intratumorly, with subsequent dosing when or if the tumour reoccurred.  Each 
treatment group contained 10 mice. The mice were monitored carefully for signs of 
distress, including behavioural changes and weight loss.  
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Results 
 
Multiple HOX genes are dysregulated in prostate tumours and cell lines 
Previous studies have revealed that HOX genes are generally dysregulated in 
malignant tissue compared to normal adult cells, and we investigated whether this is 
also the case in prostate cancer. In order to do this we obtained RNA from three cell 
lines derived from prostate cancer; DU145[20], PC3[21] and LNCaP[22], and a cell 
line derived from non-malignant prostate epithelial cells, WPMY-1[23]. QPCR 
analysis of expression levels of all 39 HOX genes shows that the tumour derived cell 
lines have significantly different patterns of HOX expression compared to WMPY-1. 
In particular, the cancer-derived lines all show higher expression of the HOXC genes 
and of HOXA5, HOXB5, HOXB7 and HOXD9, whilst WMPY-1 expresses HOX genes 
closer to the 5’ (posterior) end of each HOX cluster (Fig 1). 
 
The HOX / PBX antagonist HXR9 is cytotoxic to prostate cancer derived cell lines 
Given the elevated expression of HOX genes in both primary prostate tumours and 
cell lines, we assessed whether the prostate cancer-derived cell lines LNCaP, DU145 
and PC3 were sensitive to killing by the HOX / PBX antagonist HXR9. HXR9 is an 18 
amino acid peptide that can enter cells via endocytosis mediated by a polyarginine 
sequence. A fluorescently labelled version of this peptide was taken up by all of the 
cell lines tested (Fig 2a), and could be detected in both the cytoplasm and the 
nucleus. As a negative control, we used a second peptide, CXR9, which is identical 
to HXR9 with the exception of a single alanine substitution in the hexapeptide 
sequence. PC3 cells treated with 60µM CXR9 for two hours do not exhibit any 
apparent cytotoxicity compared to untreated cells (Fig 2b,c), whilst the same 
concentration of HXR9 results in extensive cell death (Fig 2d). 
 The cytotoxicity of HXR9 and CXR9 was determined for all three cancer-
derived lines and the non-malignant line WPMY-1 using an MTS assay. This 
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revealed that all three of the lines were sensitive to killing by HXR9, whilst WPMY-1 
cells were significantly less sensitive (Fig 2e,f).  
 
HXR9 induces apoptosis in prostate cancer derived cell lines 
To further understand the mechanism of HXR9-induced cell death, we studied the 
activity of caspase 3 in HXR9-treated cells. Caspase 3 is a key component of both 
the intrinsic and extrinsic apoptotic pathway, and can cleave a group of proteins 
involved in cell survival and proliferation. All of the prostate cancer derived cell lines 
showed a significant increase in caspase 3 activity when treated with 60µM HXR9 for 
two hours (3.7 fold for PC3 cells and 4.8 fold for both DU145 and LNCaP cells), 
whilst WPMY-1 cells do not (1.4 fold increase, p=0.0972). Treatment with CXR9 did 
not change caspase 3 activity in any of the cell lines (Fig 3a). 
 To further explore whether HXR9 induces cell death primarily through 
apoptosis, we also used a FACS based analysis for changes in the cell membrane 
that are characteristic of process and which can be detected by fluorescently labelled 
Anexxin. The assay also utilises a fluorescent DNA label (7AAD) to measure the 
membrane integrity of cells, thus allowing cells to be divided into those undergoing 
early or late stage apoptosis depending on the relative binding of the two labels (Fig 
3b). All of the cell lines tested had significantly increased levels of apoptosis after a 
two hour treatment with 60uM HXR9, compared to CXR9 treated cells. Apoptosis 
was considerably higher in the prostate cancer derived cell lines PC3, DU145 and 
LNCaP (10.6, 8.2 and 7.9 fold, respectively) than in WPMY-1 (3.8 fold).  
 To provide further confirmation that cells were undergoing apoptosis, HXR9 
and CXR9 treated cells were also treated with -VAD, a caspase inhibitor that 
blocks the apoptotic cascade. This caused a significant reduction in the proportion of 
cells undergoing apoptosis (Fig 3b), with the exception of WPMY-1 cells. 
 
HXR9 induced cell death is mediated by cFos 
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Previous studies have suggested that HXR9-induced apoptosis might be mediated 
by the elevated expression of the cFos gene [15, 17]. To further explore this, and 
determine whether it is true for prostate cancer derived cells, we used QPCR to 
assess the expression level of cFos in HXR9 and CXR9 treated cells. A two hour 
treatment with 60uM HXR9 caused a 6.2, 10.3 and 19.1 fold increase in cFos levels 
in DU145, PC3 and LNCaP cells, respectively (Fig 4a). In contrast, no significant 
increase was observed in WPMY-1 cells. 
 In order to establish whether increased cFos levels were directly responsible 
for inducing cell death, we used a siRNA knock down strategy to reduce cFos 
expression in HXR9 treated cells. DU145 cells were transfected with a random 
control siRNA (rnd siRNA), or one of two different siRNAs designed against the cFos 
sequence (siRNA1/2). Pre-treatment of DU145 cells with either of the cFos siRNAs 
was sufficient to block the increase in cFos expression upon subsequent treatment 
with HXR9, both at the mRNA and protein level (Fig 4b). This also resulted in a 
significant increase in cell survival (from 12% in cells treated with HXR9 only, to 37% 
and 56% in cells pre-treated with cFos siRNA1 and cFos siRNA2, respectively; Fig 
4c). 
 
HXR9 blocks the growth of LNCaP tumours in vivo 
The sensitivity of prostate cancer derived lines to killing by HXR9 in vitro prompted us 
to test whether this sensitivity was also apparent in vivo. We initiated flank tumours in 
nude mice using a subcutaneous injection of LNCaP cells, which have been used in 
numerous studies as a murine model of prostate cancer. Tumours were injected 
directly with HXR9 or CXR9 once the mean tumour volume had reached 100mm3. 
After 52 days the CXR9 injected tumours had, on average, increased in size 8 fold, 
whilst the average increase in HXR9 tumours was 1.5 fold (Fig 5a). Histological 
analysis of tumours revealed that whilst CXR9 treated tumours were composed 
principally of live, highly differentiated cells, those injected with HXR9 contained 
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relatively few cells and were composed to a large extent of cellular debris (Fig 5b). 
QPCR analysis of RNA extracted from tumours revealed that HXR9 induces an up 
regulation of cFos in a similar manner to that seen in vitro, suggesting that a similar 
mechanism of cell death may occur (Fig 5c).  
 
HOX genes are globally overexpressed in primary prostate tumours 
As previous studies on HOX gene expression in prostate cancer have focused only 
on single or small groups of genes, we undertook an analysis of all 39 HOX genes in 
prostate tumours and normal prostate tissue. This revealed a considerable over 
expression of many HOX family members, albeit in a heterogeneous manner with 
different HOX genes being overexpressed in different tumours. Only HOXC4 and 
HOXC6 showed consistently higher expression in the tumour compared to the 
normal prostate, with increases of 101 and 251 fold, respectively (Fig 6). Taking all of 
the HOX genes together also revealed a significantly higher global HOX expression 
in tumours (11.9 fold, Fig 6). 
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Discussion 
In this study we have shown that HOX genes are highly deregulated in prostate 
tumours and in prostate cancer derived cell lines. Whilst other studies have shown 
that this is true for a number of HOX genes, including HOXC4-8 [8, 9, 11] and 
HOXB13 [10], to our knowledge this if the first comprehensive study of HOX gene 
expression in prostate tumours. It reveals that there is a very high level of 
deregulation with the majority of HOX genes being highly expressed in tumours but 
not in normal prostate tissue. This global increase in HOX expression makes it 
difficult to study those aspects of HOX function that are redundant throughout this 
highly conserved group. Here we have used HXR9, an inhibitor of the interaction 
between HOX proteins and their common cofactor, PBX, to target a large subset of 
HOX proteins (i.e. members of paralogue groups 1-9) [15]. HXR9 causes apoptosis 
in all three of the prostate derived cells line studied, but only to a far lesser degree in 
a non-malignant cell line derived from prostate epithelium (WPMY-1). 
 Disruption of HOX / PBX regulated transcription would be expected to cause 
changes in the expression of numerous target genes, and indeed previous studies 
have shown this to be the case. However only one of these targets – cFos – has 
been shown to be directly relevant to the induction of apoptosis by HXR9 [15]. It was 
previously shown that cFos up-regulation mediated the HXR9-induced apoptosis in 
melanoma B16F10 cells, and here we show that a similar mechanism exists in the 
prostate cancer-derived cell lines DU145, PC3 and LNCaP, as siRNA knock-down of 
cFos can partially rescue each of these cell lines from HXR9 –induced cell death. 
Although cFos is classically considered to be an oncogene, there are now a number 
of reports of it acting as a pro-apoptotic gene [15, 25-28]. Our observation that 
HXR9 results in a rapid and very large increase in cFos expression indicates that the 
HOX / PBX dimer acts as a repressor of this gene. Whilst this could be a direct result 
of HOX / PBX binding to its regulatory sequences, a recent study showed that it 
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could also be due to the increased transcription of the oncogenic microRNAs miR221 
and mir222, which in turn repress cFos expression [29]. 
The prevalence of HOX over expression in prostate cancer combined with the 
novel therapeutic mechanism exploited by HXR9 suggest that it could be a 
therapeutic approach where there is small volume, well defined disease. Local 
delivery of HXR9 into a range of tumours in mice has not resulted in a local 
inflammatory response [16, 17, 19]. Therefore delivery of HXR9 directly into the 
restricted confines of a primary or locally recurrent prostate cancer is feasible, and 
would not be limited due to the risk of prostatitis. Indeed a number of studies have 
evaluated intraprostatic gene therapy and oncolytic viral therapy and have reported 
no dose-limiting toxicity. These approaches utilised current imaging technology to 
achieve the precise delivery of reagents to small volume, well defined disease [30-
32]. The application of HXR9 may be as a primary focal therapy, or where standard 
treatments approaches have failed, for example in cases of local recurrence following 
radical radiotherapy. The latter group of men currently receive ablative therapy which 
has low efficacy and is associated with significant toxicities [33]. In contrast to current 
treatments such as cryotherapy, the lack of inflammatory response associated with 
HXR9 treatment would potentially allow multiple, sequential intratumoral delivery. 
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Conclusions 
The HOX genes are highly dysregulated, and generally over-expressed in prostate 
cancer. Targeting the interaction between HOX proteins and their PBX co-factor is a 
potential therapeutic strategy in this malignancy. 
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Figure legends 
 
Figure 1. HOX gene expression in prostate cancer derived cell lines and in 
WPMY-1, which is derived from normal prostate cells. The expression of each 
gene was determined by semi-quantitative PCR and is shown relative to the house 
keeping gene GAPDH (x10000). The values shown are the mean of three 
independent experiments and the error bars represent the SEM. 
 
Figure 2. HXR9 activity in PC3 cells. (a) HXR9 enters the cytoplasm and nuclei of 
PC3 cells in vitro. PC3 cells were incubated with 5µM FITC labelled HXR9 (green) for 
two hours and then stained with Hoechst S769121 (a fluorescent dye staining nuclei 
yellow). Scale bar: 5µm (b-d) Light micrographs of PC3 cells either untreated (b) or 
incubated with 60µM CXR9 (c) or HXR9 (d) for two hours. Scale bar: 100µm (e) 
Survival curves for PC3, DU145, LNCaP and WPMY-1 cells treated with HXR9. (f) 
IC50 values for HXR9 treatment. The negative control peptide CXR9 was not toxic at 
any of the concentrations tested for any of the cell lines (i.e. the IC50 > 100µM). Error 
bars represent the SEM (n=3), the p values are with respect to WPMY-1.  
 
Figure 3. HXR9 induces apoptosis in prostate cancer cells. (a) Caspase 3 activity 
in PC3, DU145, LNCaP and WPMY-1 cells treated with 60µM HXR9 or CXR9 for two 
hours. ‘Unt’ - untreated cells. (b) PC3, DU145, LNCaP and WPMY-1 cells were 
treated with 60µM HXR9 (HX) or CXR9 (CX) for two hours and cells were assessed 
for apoptosis through Annexin / 7AAD staining. The % of cells in apoptosis is shown. 
Cells were also treated with the Caspase inhibitor ZVAD (ZV) alone or in combination 
with HXR9 (HX ZV). Error bars show the SEM. *p<0.05, **p<0.01 with respect to 
untreated cells. 
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Figure 4. HXR9 induced apoptosis is mediated by cFos. (a) QPCR analysis of 
cFos expression in response to treatment of PC3, DU145, LNCaP and WPMY-1 cells 
with 60µM HXR9 or CXR9 for two hours. ‘Unt’ – untreated cells. (b) Knock down of 
cFos expression using siRNA. DU145 cells were incubated with transfection reagent 
alone (‘Transf only’), or were transfected with a control siRNA with a random 
sequence (‘rnd siRNA’), or with one of two siRNA targeting cFos (‘cFos siRNA 1’ and 
‘cFos siRNA 2’). Cells were also either treated with 60µM HXR9 or CXR9, or with 
HXR9 in combination with one of the transfected cFos specific siRNAs (‘HXR9 + s1’ 
or ‘HXR9 + s2’). The expression of cFos in treated cells was determined either at the 
RNA level using QPCR (upper section) or at the protein level using western blotting 
(lower section). (c) The % cell survival for each of the treatments described in (b). 
Knock down of cFos in HXR9 treated cells results in a statistically significant 
decrease in cell death. Error bars show the SEM. *p<0.05, ***p<0.001 with respect to 
untreated cells. 
 
Figure 5. HXR9 retards LNCaP tumour growth in vivo. (a) Growth curve for 
LNCaP tumours treated intratumorally with a single dose of HXR9 or CXR9 when the 
tumour volume reached 100mm3. Error bars show the SEM. (b) Section through 
LNCaP tumours in mice treated with CXR9 or HXR9. The CXR9 treated section 
shows highly undifferentiated tumour cells, whilst the HXR9 section shows the 
remains of dead tumour cells. Scale bar: 20µm. (c) Expression of cFos in tumours 
treated with HXR9 or CXR9, shown as a ratio between cFos and GAPDH transcripts 
detected by QPCR. Error bars show the SEM.  
 
Figure 6. HOX gene expression in normal prostate tissue and prostate 
tumours. The expression of each gene was determined by semi-quantitative PCR 
and is shown relative to the house keeping gene GAPDH (x10000). The horizontal 
bar represents the mean and the error bars represent the SEM. 
